Drug Profile
Research programme: H1N1 influenza virus therapies - Sarepta Therapeutics/Defense Threat Reduction Agency
Alternative Names: Swine flu therapies - AVI/DTRALatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator AVI BioPharma
- Developer Sarepta Therapeutics
- Class Antisense oligonucleotides
- Mechanism of Action Immunomodulators; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Influenza A virus H1N1 subtype